Benzinga | Oct 13, 2021 01:38PM EDT

Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

--Data suggest SINTAX(tm) medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery--

--EDP1867 reduced disease severity and incidence of relapse in murine model of multiple sclerosis--

--Data support development of EDP1867 for the treatment of neuroinflammatory diseases--